Expression of Ku86 confers favorable outcome of tonsillar carcinoma treated with radiotherapy

Head Neck. 2003 Apr;25(4):313-21. doi: 10.1002/hed.10199.

Abstract

Background: To determine possible molecular markers for predicting radiosensitivity in squamous cell carcinoma, we have examined the relationship between pretreatment expression of the DNA damage recognition complex DNA-PK, its in vitro substrates, p53 and MDM2, local tumor control after radiotherapy (RT), and patient survival.

Methods and materials: Formalin-fixed tumor biopsy specimens from 79 previously untreated patients with tonsillar carcinoma were analyzed by immunohistochemical methods.

Results: Tumors expressing high levels of Ku86 had better locoregional control in contrast to tumors expressing low levels of Ku86 (p =.023). Survival of patients with tumors expressing high levels of DNA-PKcs was significantly better than survival of patients with tumors expressing low levels of DNA-PKcs (p =.0024). p53 and MDM2 status alone did not correlate with survival of patients. However, patients with p53 tumors and high DNA-PKcs expression had significantly better survival than patients with p53+ tumors expressing low levels of DNA-PKcs (p =.0018). Furthermore, survival of patients with high expression of DNA-PKcs or Ku86 and low MDM2 levels was significantly better when compared with survival of patients with low DNA-PKcs or Ku86 and high MDM2 (p =.0017 and p =.0034, respectively).

Conclusions: High expression of DNA-PKcs/Ku86 in combination with p53 negativity in tonsillar carcinoma correlates with better survival of patients. Identifying tumors with a phenotype predicting poor survival may be used to optimize treatment of patients with radioresistant tumors.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antigens, Nuclear / analysis*
  • Antigens, Nuclear / genetics*
  • Arabidopsis Proteins / analysis
  • Arabidopsis Proteins / genetics
  • Carcinoma, Squamous Cell / genetics*
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / radiotherapy*
  • DNA Helicases*
  • DNA-Activated Protein Kinase
  • DNA-Binding Proteins / analysis*
  • DNA-Binding Proteins / genetics*
  • Female
  • Gene Expression / genetics*
  • Humans
  • Ku Autoantigen
  • Male
  • Middle Aged
  • Nuclear Proteins*
  • Outcome Assessment, Health Care*
  • Predictive Value of Tests
  • Protein Serine-Threonine Kinases / analysis
  • Protein Serine-Threonine Kinases / genetics
  • Proto-Oncogene Proteins / analysis
  • Proto-Oncogene Proteins / genetics
  • Proto-Oncogene Proteins c-mdm2
  • Survival Rate
  • Tonsillar Neoplasms / genetics*
  • Tonsillar Neoplasms / pathology
  • Tonsillar Neoplasms / radiotherapy*
  • Tumor Suppressor Protein p53 / analysis
  • Tumor Suppressor Protein p53 / genetics

Substances

  • Antigens, Nuclear
  • Arabidopsis Proteins
  • DNA-Binding Proteins
  • KU70 protein, Arabidopsis
  • Nuclear Proteins
  • Proto-Oncogene Proteins
  • Tumor Suppressor Protein p53
  • MDM2 protein, human
  • Proto-Oncogene Proteins c-mdm2
  • DNA-Activated Protein Kinase
  • PRKDC protein, human
  • Protein Serine-Threonine Kinases
  • DNA Helicases
  • XRCC5 protein, human
  • Xrcc6 protein, human
  • Ku Autoantigen